These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15100154)

  • 1. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.
    Dietz AB; Souan L; Knutson GJ; Bulur PA; Litzow MR; Vuk-Pavlovic S
    Blood; 2004 Aug; 104(4):1094-9. PubMed ID: 15100154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
    Appel S; Boehmler AM; Grünebach F; Müller MR; Rupf A; Weck MM; Hartmann U; Reichardt VL; Kanz L; Brümmendorf TH; Brossart P
    Blood; 2004 Jan; 103(2):538-44. PubMed ID: 14504105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
    Seggewiss R; Loré K; Greiner E; Magnusson MK; Price DA; Douek DC; Dunbar CE; Wiestner A
    Blood; 2005 Mar; 105(6):2473-9. PubMed ID: 15572591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.
    Cwynarski K; Laylor R; Macchiarulo E; Goldman J; Lombardi G; Melo JV; Dazzi F
    Leukemia; 2004 Aug; 18(8):1332-9. PubMed ID: 15190258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
    Matei D; Chang DD; Jeng MH
    Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
    Larmonier N; Janikashvili N; LaCasse CJ; Larmonier CB; Cantrell J; Situ E; Lundeen T; Bonnotte B; Katsanis E
    J Immunol; 2008 Nov; 181(10):6955-63. PubMed ID: 18981115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Merchant MS; Woo CW; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?
    Kälsch AI; Soboletzki M; Schmitt WH; van der Woude FJ; Hochhaus A; Yard BA; Birck R
    Clin Exp Immunol; 2008 Mar; 151(3):391-8. PubMed ID: 18190601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An in vitro study of the cytogenetic and cytotoxic effects of imatinib mesylate, STI571 on murine erythroleukemia GM-86 cells.
    Kirk MJ; Fotiadis NA; Majumdar SK
    J Chemother; 2006 Feb; 18(1):49-55. PubMed ID: 16572894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
    Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
    J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carvedilol in glioma treatment alone and with imatinib in vitro.
    Erguven M; Yazihan N; Aktas E; Sabanci A; Li CJ; Oktem G; Bilir A
    Int J Oncol; 2010 Apr; 36(4):857-66. PubMed ID: 20198329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
    Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.
    Mumprecht S; Matter M; Pavelic V; Ochsenbein AF
    Blood; 2006 Nov; 108(10):3406-13. PubMed ID: 16873671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment.
    Maggio R; Peragine N; De Propris MS; Vitale A; Elia L; Calabrese E; Della Starza I; Intoppa S; Milani ML; Guarini A; Foà R
    Cancer Immunol Immunother; 2011 Apr; 60(4):599-607. PubMed ID: 21240485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
    Vittal R; Zhang H; Han MK; Moore BB; Horowitz JC; Thannickal VJ
    J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models.
    Vitali R; Mancini C; Cesi V; Tanno B; Mancuso M; Bossi G; Zhang Y; Martinez RV; Calabretta B; Dominici C; Raschellà G
    Clin Cancer Res; 2008 Jul; 14(14):4622-30. PubMed ID: 18628477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
    Shimizu T; Miyakawa Y; Iwata S; Kuribara A; Tiganis T; Morimoto C; Ikeda Y; Kizaki M
    Exp Hematol; 2004 Nov; 32(11):1057-63. PubMed ID: 15539083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
    Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
    Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.